Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TOOKAD (padeliporfin) VTP for low grade upper tract urothelial cancer
2020-004494-41Phase 3Active
- Sponsor
- Steba Biotech
- Start
- Mar 2021
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of padeliporfin VTP in upper tract urothelial carcinoma (UTUC), Renal pelvis urothelial carcinoma (UTUC) and ureteral urothelial carcinoma, sponsored by Steba Biotech. Primary endpoint: Complete response in ipsilateral upper tract. Started Mar 2021; status: active.
02
Drugs
padeliporfin VTP
03
Conditions
upper tract urothelial carcinoma (UTUC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinoma
Beyond the preview
Go deeper on 2020-004494-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004494-41.